Introduction: In recent years, the development of artificial intelligence (AI) technologies, including machine learning, deep learning, and large language models, has significantly supported clinical work. Concurrently, the integration of artificial intelligence with the medical field has garnered increasing attention from medical experts. This study undertakes a dynamic and longitudinal bibliometric analysis of AI publications within the healthcare sector over the past three decades to investigate the current status and trends of the fusion between medicine and artificial intelligence.Methods: Following a search on the Web of Science, researchers retrieved all reviews and original articles concerning artificial intelligence in healthcare published between January 1993 and December 2023. The analysis employed Bibliometrix, Biblioshiny, and Microsoft Excel, incorporating the bibliometrix R package for data mining and analysis, and visualized the observed trends in bibliometrics.Results: A total of 22,950 documents were collected in this study. From 1993 to 2023, there was a discernible upward trajectory in scientific output within bibliometrics. The United States and China emerged as primary contributors to medical artificial intelligence research, with Harvard University leading in publication volume among institutions. Notably, the rapid expansion of emerging topics such as COVID-19 and new drug discovery in recent years is noteworthy. Furthermore, the top five most cited papers in 2023 were all pertinent to the theme of ChatGPT.Conclusion: This study reveals a sustained explosive growth trend in AI technologies within the healthcare sector in recent years, with increasingly profound applications in medicine. Additionally, medical artificial intelligence research is dynamically evolving with the advent of new technologies. Moving forward, concerted efforts to bolster international collaboration and enhance comprehension and utilization of AI technologies are imperative for fostering novel innovations in healthcare.
Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis. However, their relationship remains unknown. This study aims to demonstrate the regulation and role of AVP in aldosterone synthesis in the heart. Rats were subjected to a sham operation or myocardial infarction (MI) by ligating the coronary artery. Cardiac function and fibrosis were assessed using echocardiography and immunohistochemical staining, respectively. In addition, the effects of AVP stimulation on cardiac microvascular endothelial cells (CMECs) were studied using ELISA, real-time PCR, and Western blotting. Compared with the rats having undergone a sham operation, the MI rats had an increased LVMI, type I collagen composition, and concentrations of aldosterone and AVP in the heart but decreased cardiac function. As the MI rats aged, the LVMI, type I collagen, aldosterone, and AVP increased, while the LVMI decreased. Furthermore, AVP time-dependently induced aldosterone secretion and CYP11B2 mRNA expression in CMECs. The p-CREB levels were significantly increased by AVP. Nevertheless, these effects were completely blocked by SR49059 or partially inhibited by KN93. This study demonstrated that AVP could induce the secretion of local cardiac aldosterone, which may involve CaMK and CREB phosphorylation and CYP11B2 upregulation through V1 receptor activation.
15 July 2025 in Frontiers in Cardiovascular Medicine
Background: Coronary slow flow (CSF), characterized by delayed coronary perfusion without significant coronary artery stenosis, remains a diagnostic challenge due to its elusive pathophysiology. This retrospective study aimed to evaluate the association between the thrombin-antithrombin (TAT) complex and CSF.Patients and methods: Ninety-one CSF patients and 74 subjects with normal coronary flow were recruited in this cohort. Coronary artery blood flow was quantified using the thrombolysis in myocardial infarction frame count (TFC) method. Plasma TAT complex levels were measured via chemiluminescent immunoassay. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the predictive value of TAT for CSF.Results: Compared with patients without CSF, patients with CSF showed higher plasma levels of TAT complex, total cholesterol, and low-density lipoprotein cholesterol, all of which were also positively correlated with TFC. However, multivariate logistic regression identified TAT as the only independent predictor of CSF after adjustment (OR: 1.71, 95% CI: 1.39–2.10, p < 0.001). More specifically, ROC analysis revealed that a plasma TAT complex levels of 3.875 ng/ml predicted CSF with a specificity of 89.2% and a sensitivity of 62.6%.Conclusion: Elevated plasma TAT complex levels are strongly associated with CSF and may serve as a candidate diagnostic biomarker.
Although fibronectin has been associated with the pathogenesis of atherosclerosis, little is currently known about the relationship between plasma fibronectin and coronary heart disease (CHD). This retrospective study aimed to determine the predictive value of plasma fibronectin for CHD and its severity. A total of 1644 consecutive patients who underwent selective coronary angiography were recruited into the present study. The characteristics and results of the clinical examination of all patients were collected. Logistic regression analyses were performed to determine the predictive value of plasma fibronectin for the presence and severity of CHD. Compared with non-CHD patients, the CHD patients showed significantly higher plasma levels of troponin I and creatine kinase isoenzyme, along with lower plasma levels of fibronectin. However, no significant differences were detected in plasma fibronectin among patients with different grades of CHD. The logistic regression model showed that plasma fibronectin remained an independent predictor of CHD after adjustment with a 1.39-fold increased risk for every 1 SD decrease in plasma fibronectin. Nevertheless, plasma fibronectin could not predict the severity of CHD determined by the number of stenosed vessels and the modified Gensini score. This study demonstrated that lower plasma fibronectin might be an independent predictor of CHD, but it may be of no value in predicting the severity of CHD.
24 March 2026 in Frontiers in Cardiovascular Medicine
Background: Interleukin-6 (IL-6) is associated with the pathogenesis of heart failure (HF) and an increased HF risk in people without previous myocardial infarction. However, little is currently known about the correlation between IL-6 and acute decompensated heart failure (ADHF). Objective: To determine whether IL-6 could serve as a diagnostic biomarker for ADHF in Chinese patients without acute myocardial infarction. Patients and methods: A total of 122 patients were included in our study [58 ADHF, 64 chronic HF (CHF)]. Plasma IL-6 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the diagnostic value of IL-6. Results: Plasma levels of IL-6 and NT-proBNP were higher in ADHF patients than CHF patients. IL-6 correlated positively with NT-proBNP, heart rate, and left ventricular end-diastolic dimension, and inversely with left ventricular ejection fraction. After adjustment, IL-6 remained independently associated with ADHF (OR = 1.461, 95% CI: 1.053–2.028, p = 0.023). The optimal cut-off value of IL-6 for ADHF diagnosis was 5.00 pg/mL, and the sensitivity, specificity, and Youden index were 81.0%, 87.5%, and 0.685, respectively. Conclusions: IL-6 is independently associated with ADHF and shows promising diagnostic accuracy. The cut-off of 5.00 pg/mL provides a novel reference for Chinese ADHF patients without AMI, offering clinical evidence for research on inflammation-related biomarkers of cardiovascular diseases. Combined use with NT-proBNP may enhance diagnostic accuracy, but prospective validation is needed.
Irbesartan improves ventricular remodeling (VR) following myocardial infarction (MI). This study investigates whether irbesartan attenuates VR by reducing aldosterone production in the heart and its underlying mechanisms. MI was induced in male Sprague–Dawley rats through coronary artery ligation. The MI rats were randomly assigned to two groups: one received a vehicle, and the other received 100 mg/kg/day of irbesartan for 5 weeks. Cardiac function and myocardial fibrosis were assessed using echocardiography and Masson’s trichrome staining, respectively. The impact of angiotensin II (Ang II) stimulation on cardiac microvascular endothelial cells (CMECs) from commercial sources was determined using ELISA, real-time PCR, and Western blotting. Irbesartan reduced left ventricular mass index, collagen composition, and aldosterone levels while enhancing cardiac function in MI rats. In vitro, Ang II time-dependently stimulated aldosterone secretion and CYP11B2 mRNA expression in CMECs (p < 0.05). Additionally, Ang II significantly upregulated p-CREB protein levels. However, these effects were abrogated by irbesartan and partially attenuated by CaMK inhibitor KN93 (p < 0.05). In conclusion, our study demonstrated that improvement in VR by irbesartan coincided with reduced CREB phosphorylation in CMECs and reduced aldosterone synthesis in the non-infarcted tissue. These effects may be mediated by blocking the AT1 receptor.